

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Friday 17 July 2015

ASX ANNOUNCEMENT – GENERA BIOSYSTEMS LIMITED (ASX: GBI)

GENERA’S AMPASAND ASSAYS TO BE OFFERED IN INDIAN MARKET

Genera Biosystems Limited (**‘Genera’**) is pleased to announce that it has entered into a non-exclusive Commercial Supply and Distribution Agreement (**‘CSDA’**) with Genecell Diagnostics Private Limited (**‘Genecell’**) to supply its AmpaSand® based molecular diagnostics (**‘MDx’**) assays to two selected pathology groups in the Indian market.

Under the terms of the CSDA Genecell has been granted the right to distribute Genera’s AmpaSand MDx assays to its CureHealth Diagnostics pathology lab subsidiary and SRL Diagnostics. Genera is working with Genecell to support it to undertake its internal assay validation in late August with commercial shipments of kits anticipated to take place late in Q3 CY2015 and first customer receipts expected early in Q4 of CY2015.

CureHealth operates a specialised pathology MDx reference laboratory in New Delhi servicing the Delhi and National Capital Region (NCR) territory markets and has an exclusive marketing agreement with SRL Diagnostics for its HPV mRNA test in the cervical cancer screening domain, pan India. SRL is the leading and reputed national lab network in India with a 43% market share of the organised Indian pathology sector. With 258 labs (of which 12 are high-end laboratories) and 6,300 collection points, SRL has the second largest pathology network in Asia conducting more than 107,000 tests a day ranging from simple to high-end tests.

Richard Hannebery, Genera Chief Executive Officer commented, “India represents an enormous opportunity for Genera and our high quality MDx menu as better healthcare awareness drives demand for quality pathology services. There is a significant middle class population in India, who in consultation with their physicians want to access the most advanced diagnostic technology that the market can offer. We believe that Genecell is an ideal partner to support Genera’s launch plan to penetrate this considerable market opportunity.”

India's medical diagnostics market size is currently worth about US\$3.2 billion per annum (Rs 20,000 crore), of which 10 per cent is in the organised pathology sector with substantial market fragmentation and challenges existing outside of this space. Richard Hannebery added, “Given the highly fragmented nature of the Indian market and the requirement for strong local knowledge and relationships, it is imperative that we enter with the right partner. In the principals of Genecell, who we have now known for a few years, we believe we have credible partners with whom we can have a trust-based and mutually beneficial working relationship.”

Genecell director and founder Dr Dinesh Gupta Ph.D added, “We are very excited to partner with Genera in bringing its AmpaSand MDx menu into India. Genecell knows the Indian market well and

to date we have invested considerable time and effort in launching a compelling MDx test menu with our pathology partners. The opportunity to work with Genera to introduce its own cutting edge MDx menu in a complementary manner to our existing offering is a win-win for both of us. Our exclusive working relationship with SRL is well appreciated in the Indian diagnostic industry and we see enormous potential for AmpaSand based MDx tests being leveraged into India's premier pathology network.

"The opportunity that we see for RTI-plex specifically is substantial on the public health front with chronic upper respiratory tract diseases in India posing a major public health challenge. Dramatic increase in tobacco use, urban vehicular pollution, industrial effusion, rural agricultural waste and microbial transmission are major causative factors and when coupled with low national healthcare priority and limited fiscal resources it makes fighting against respiratory diseases a daunting mission. A countrywide anti-tobacco campaign and seasonal preventive measures against endemic viral flu due primarily to H1N1 are the only cognizable major government initiatives operative in the public healthcare domain.

"Adding RTI-plex as a one-step test may provide a standardized management program for asthma and chronic obstructive pulmonary disease (COPD). The symptoms of these diseases, while not generally caused by microbial infection, can be exacerbated by viral and bacterial infections that can be detected by RTI-plex. Genera's proprietary AmpaSand bead-based technology that allows simultaneous detection of as many as fifteen common pathogens that cause a variety of respiratory diseases can bring tremendous value in an environment of limited fiscal resources", Dr Gupta said.

IVD Partnering Discussions

Genera's discussions to date with its prospective global IVD partners has demonstrated a consistent and significant interest being aired by global IVD's in the emerging Asian markets – particularly India.

Richard Hannebery commented, "While this deal is significant for Genera it is important to note that the door remains open for our potential partners to attack this market directly via their well-established investment in sales, service and support infrastructure. Genera remains committed to undertaking an appropriately structured global partnering deal with a well-credentialed IVD company in the coming 2-3 months that will see our world class multiplexed MDx platform launched in numerous jurisdictions around the world."

Predictors 3 Clinical Study

Genera is pleased to announce that the PapType® 6,000 patient Predictors 3 HPV screening study conducted by the Wolfson Institute of Preventive Medicine, London was successfully completed in late May. The company anticipates the clinical data being made available to it in the next month in order to facilitate the sharing of this pivotal clinical data under confidentiality with its prospective global IVD partners.

Genera is also pleased to announce that Prof Jack Cuzick, head of the Centre for Cancer Prevention in London, and John Snow Professor of Epidemiology at the Wolfson Institute will be Genera's guest at the Peter MacCallum Cancer Centre, Melbourne in late July.

"Dr Karl Poetter, myself and the rest of the team look forward to hosting Prof Cuzick later this month at the Peter Mac and further discussing the merits of our uniquely positioned home grown PapType HPV test within a screening setting", Richard Hannebery added. Genera remains committed to best

position its simultaneous genotyping HPV test, PapType® when the new national cervical screening program in Australia is implemented in 2017 and selected HPV tests are included under the Medicare Benefits Schedule.

Volumes of HPV testing in the Australian market are expected to grow to 1.3m tests per annum with the introduction of the new cervical cancer screening regime. The global market opportunity for HPV testing is expected to exceed US\$2 billion per annum as numerous countries follow Australia's lead in replacing the traditional pap smear with HPV testing as the front line screening tool in the fight against cervical cancer in women.

Genera will provide a comprehensive market update on all operational matters in its quarterly business update anticipated to be released to the ASX on Friday, 31 July.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com

About Genera Biosystems : Genera Biosystems Limited ("GBI") is an Australian Stock Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD approved with several additional products in the company's development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.